2009 Frost & Sullivan RNAi Award

RXi Pharmaceuticals Wins 2009 RNAi Technology Innovation of the Year Award from Frost & Sullivan

RXi Pharmaceuticals (Nasdaq: RXII) is a biopharmaceutical company pursuing the development and commercialization of novel treatments for human diseases using a technology called RNA interference (RNAi). RNAi was discovered by our co-founder, Dr. Craig Mello, who was awarded the 2006 Nobel Prize for his groundbreaking work in this area. By harnessing the power of RNAi, we believe that RXi Pharmaceuticals may be able to develop a new class of therapeutic products that could have a number of distinct advantages over today’s drugs.

 

RNAi is a naturally occurring mechanism for the regulation of gene expression that has the potential to selectively inhibit the activity of any human gene.  As a result, RNAi may potentially treat human diseases by “turning-off” genes and blocking the production of disease causing proteins before they are made.

 

RXi was founded by world-leading researchers in the field of RNAi, began operations in January of 2007 and started trading on the Nasdaq in March of 2008.  Our research and development efforts are led by an outstanding team with a strong track record of discovering new technologies and moving RNA based drugs into the clinic.    

 

Investor Relations

Webcast:

RXi Pharmaceuticals Corporation at Jefferies 2010 Global Life Sciences Conference
6/10/10  3:00 p.m. ET


Press Release: 06/10/10
RXi Pharmaceuticals Announces New Focused Therapeutic Strategy for its Next Generation RNAi Technology 


Corporate Governance

RXi in the News
Worcester Business Journal
Shop Talk: Q&A with Noah Beerman, RXi Pharmaceuticals

Life Science Leader, March 2010
Noah Beerman speaks on RXi’s foundation and its missions for the future.  Plus, Dr. Craig Mello explains the potential of RNAi.

More News >
Nobel Prize
RXi's founder, Dr.Craig Mello, wins the Nobel Prize in Medicine
Read More >

NOVA's Science NOW
Watch the videos